1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Heron Therapeutics, Inc.

Heron Therapeutics, Inc.

HRTX
Heron Therapeutics, Inc.US flagNASDAQ Capital Market
0.48
USD
+0.00
- -
75.37MMarket Cap
Heron Therapeutics, Inc.
HRTX
(NASDAQ Capital Market)

Recent

price

0.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.66
0.11
- -
- -
- -
- -
0.03
0.57
1.06
1.78
0.98
0.88
0.99
0.92
0.95
0.93
0.86
Revenue per Share
-3.7
-1.96
-1.91
-3.42
-2.87
-2.95
-4.57
-3.65
-2.44
-2.5
-2.5
-2.24
-1.67
-0.8
-0.09
-0.12
-0.18
Basic EPS, GAAP
-2.8
-1.37
-1.47
-2.63
-2.32
-2.41
-3.62
-3.2
-2.75
-1.61
-2.11
-2.1
-1.36
-0.44
-0.16
-0.17
-0.12
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-74.63
-26.32
-15.01
-14.76
-11.85
-12.47
-15.44
-14.49
-13.12
-14.24
-15.33
-16.37
-16.46
-13.79
-12.58
-11.62
-11.09
Book Value per Share
0.66
2.62
4.24
4.27
2.37
3.57
-0.56
2.43
5.06
4.94
2.61
0.79
0.12
-0.25
-0.22
0.08
0.05
Tangible Book Value per Share
2
6
12
16
27
33
38
54
73
82
91
98
109
138
152
167
176
Basic Weighted Avg Shares
1
1
- -
- -
- -
- -
1
31
77
146
89
86
108
127
144
155
151
Sales/Revenue/Turnover
-763.57
-1,712.38
- -
- -
- -
- -
-13,363.17
-632.36
-237.42
-144.34
-257.41
-252.27
-162.21
-87.07
-7.99
-1.64
-6.94
Operating Margin (%)
- -
- -
- -
- -
1
1
1
2
2
2
3
3
3
3
2
2
2
Depreciation Expense
-7
-12
-23
-55
-76
-98
-173
-197
-179
-205
-227
-221
-182
-111
-14
-20
-31
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-564.64
-1,828.79
- -
- -
- -
- -
-13,537.37
-641.87
-230.84
-140.27
-256.41
-255.58
-169.05
-87.02
-9.41
-13.04
-20.53
Profit Margin (%)
1
15
50
66
60
115
23
125
355
382
212
183
123
109
118
142
138
Working Capital
- -
- -
- -
- -
- -
- -
50
- -
- -
12
15
157
155
177
175
141
142
LT Debt
1
16
52
69
63
118
-21
131
370
404
236
78
14
-34
-34
14
9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
- -
- -
LT Borrowings
140
141
142
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
8
1
1
Shares Outstanding
183
188
189
Market Capitalization
199
216
140

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
229
238
229
Cash, Cash Equivalents & STI
55
47
45
Accounts Receivable, Net
81
90
84
Inventories
70
93
93
Total Current Liabilities
90
96
91
Payables & Accruals
89
87
91
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-132.87%
-128.71%
-142.59%
Free Cash Flow
0.13%
-24.87%
15.16%
Net Income, GAAP
0.88%
-19.74%
48.71%
Sales/Revenue/Turnover
- -
12.21%
7.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
35
36
33
41
144
2025
39
37
38
41
155
2026
35
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.06
-0.03
0.02
-0.09
2025
0.02
-0.02
-0.1
-0.02
-0.12
2026
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Newron Pharmaceuticals S.p.A. (NWRN.SW)
Grace Therapeutics, Inc. (GRCE)
Green Cross Cell Corporation (031390.KQ)
Biome Australia Limited (BIO.AX)
Ceryvyn Therapeutics Ltd (CYV.AX)
YD Bio Limited Ordinary Shares (YDES)
Business
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a commercial-stage biotechnology company that develops and commercializes therapies to advance the standard of care for acute care and oncology patients through its proprietary Biochronomer drug delivery technology. The company offers ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and low-dose meloxicam for postoperative pain management in adults undergoing small- to medium-open surgical procedures via a single administration; APONVIE, an intravenous aprepitant injection indicated for preventing postoperative nausea and vomiting (PONV) in adults; CINVANTI, an intravenous fosaprepitant for chemotherapy-induced nausea and vomiting (CINV) approved as both a 30-minute infusion and a 2-minute injection; and SUSTOL, a subcutaneous extended-release granisetron injection utilizing Biochronomer technology to maintain therapeutic levels for at least five days for CINV prevention in adults receiving moderately emetogenic chemotherapy or anthracycline plus cyclophosphamide regimens. Heron Therapeutics primarily serves U.S. healthcare providers including surgeons, oncologists, nurses, and pharmacists through a targeted sales force and specialty distributors, with products registered in over 30 foreign countries spanning Europe, Asia-Pacific, and Latin America though commercial focus remains domestic. Founded in 1983 and headquartered in Cary, North Carolina following relocation from San Diego, California, the company recently completed a comprehensive capital restructuring in 2025 that reduced total debt from $175 million to $145 million, secured a senior credit facility of up to $150 million from Hercules Capital due in 2030 with $110 million committed at closing and additional tranches tied to milestones, launched dedicated sales teams for ZYNRELEF and APONVIE in Q3 2025 to drive adoption, transitioned ZYNRELEF to a Vial Access Needle optimizing hospital and ambulatory surgical center preparation, obtained a permanent CMS J-code for ZYNRELEF effective October 1, 2025 to enhance reimbursement, and appointed Brett Fleshman as Chief Business Officer in August 2024 and Thomas Cusack to its board in October 2025.

Company News

APIChatGPT

  • zacks.com

    New Strong Sell Stocks for July 15th

  • globenewswire.com

    U.S. District Court Issues Decision Regarding CINVANTI® Patents

  • seekingalpha.com

    Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

  • marketbeat.com

    Heron Therapeutics Q1 Earnings Call Highlights

  • zacks.com

    Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

  • zacks.com

    Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

  • globenewswire.com

    Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

  • zacks.com

    Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

  • globenewswire.com

    Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

  • zacks.com

    These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

  • seekingalpha.com

    Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript

  • zacks.com

    Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say

  • globenewswire.com

    Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

  • seekingalpha.com

    Heron: Near The Bottom Of A Trading Range Despite Positives

  • globenewswire.com

    Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

  • defenseworld.net

    New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX

  • defenseworld.net

    Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast

  • globenewswire.com

    Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

  • defenseworld.net

    Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of “Hold” from Analysts

  • defenseworld.net

    Congress Park Capital LLC Acquires 621,908 Shares of Heron Therapeutics, Inc. $HRTX